Cystic fibrosis gene therapy - CFTR-cationic lipid complex

Drug Profile

Cystic fibrosis gene therapy - CFTR-cationic lipid complex

Alternative Names: CFTR gene-cationic lipid complex; CFTR gene-cytofectin complex; Cystic fibrosis gene therapy - CFTR-cytofectin complex

Latest Information Update: 15 Dec 2016

Price : $50

At a glance

  • Originator Genzyme Corporation
  • Developer Vical
  • Class Gene therapies
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cystic fibrosis

Most Recent Events

  • 15 May 2001 Discontinued-I for Cystic fibrosis in USA (Intranasal)
  • 20 Feb 1997 Phase-I clinical trials for Cystic fibrosis in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top